The best Side of Glibornuride
All enrolled patients who acquired not less than a single dose of zosuquidar or placebo during induction have been monitored for that prevalence of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse activities ended up related to the duration of prolonged and important myelosuppression as is anticipated